Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Principia Biopharma, Inc.

http://www.principiabio.com/

Latest From Principia Biopharma, Inc.

Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities

The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.

Clinical Trials Companies

BTK Inhibitors Are The Next Big Race In MS

BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.

Clinical Trials Business Strategies

Sanofi Maps Out R&D Expectations For 2H 2021

Sanofi has transformed the productivity of its R&D pipeline over the past several years, and late-stage clinical data readouts are expected in the second half of this year for new anticancer drugs, a candidate pemphigus therapy and a COVID-19 vaccine.

Clinical Trials Cancer

Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader

Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.

Immune Disorders Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register